DON’T MISS A DIAGNOSIS WITH BIOMÉRIEUX SOLUTIONS
FOR C. DIFFICILE DETECTION
Clostridioides difficile (C. difficile) is one of the most challenging Healthcare Associated Infections (HAI)1. C. difficile is usually contracted in the healthcare setting and is connected to antibiotic treatment. C. difficile infection (CDI) generates costly treatment, patient isolation and longer hospital stays1.
The rise of Community Acquired Infections is of concern and now accounts for 35-48% of CDI diagnosis in the US2. During a point-prevalence study in Europe, the CDI positivity was found to be at 1.3% in community samples, and half of community CDI cases were undetected because of absence of clinical suspicion, representing 3 times more undiagnosed adults in the community compared with hospitals3.
Continued appropriate infection control, antibiotic use, and diagnostic testing are important in decreasing C. difficile cases1.
Based on the ACG, IDSA and ESCMID guidelines, the diagnosis of CDI should include a two-step approach with both a highly sensitive and a highly specific testing methods to help distinguish colonization from active infection 2,4,5. At bioMérieux we have methods to help you diagnose C. difficile in routine stool testing.
In the case of C. difficile in the community, the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel is the solution of choice because of its high sensitivity and thanks to its broad menu, helping to detect unsuspected pathogens6.
In the context of hospital acquired C. difficile infection, the choice between BIOFIRE GI Panel and VIDAS® GDH should be made based on the clinical picture of each patient.
* VIDAS® C. difficile GDH
** VIDAS® C. difficile Toxin A & B
bioMérieux offers a comprehensive solution for all the steps of the CDI diagnosis and management.
BIOFIRE® FILMARRAY® Gastrointestinal Panel
The BIOFIRE GI Panel is a syndromic PCR test for infectious disease diagnostic. The BIOFIRE GI Panel is a comprehensive panel that tests stool in Cary Blair for 22 bacteria, viruses, and parasites commonly associated with gastroenteritis.
It includes C. difficile in its menu which is found in about 15% of positive BIOFIRE GI Panel (know more).
It has been demonstrated that the BIOFIRE GI Panel can lead to more rational patient isolation, lowering the rates of nosocomial transmission of many GI pathogens, in addition it can detect unsuspected infections in C. difficile negative patients6.
VIDAS®
VIDAS® C. Difficile immunoassays are adapted to current diagnosis guidelines with: VIDAS® GDH higly sensitive test for the screening and VIDAS® CDAB highly specific test for the toxins detection.
NEW IVDR: VIDAS® GDH and VIDAS® CDAB are already CE Marked under the new In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR)
*see VIDAS® GDH and VIDAS® CDAB package insert performances
CHROMID® C. DIFFICILE
For epidemiology purpose or outbreak management the culture of Clostridioides difficile remains necessary. CHROMID®C.difficile highlights pathogens of interest within 24h and reduces unnecessary confirmation tests and incubation time!
EPISEQ®
In order to prevent transmission or the spread of an outbreak, our BIOMERIEUX EPISEQ® portfolio support the analysis of NGS data for C.diff bacterial typing and assess the impact of C.diff infection on the patient microbiome.
EPISEQ® CS for clinical pathogens outbreak monitoring
Next Generation Sequencing software to determine the transmission pathway in case of C. difficile outbreak. EPISEQ® CS includes a highly discriminant bacterial typing technics based on raw Whole Genome Sequencing data and delivers the list of resistance and virulence genes present on the bacterial genome.
EPISEQ® 16S for microbiome profiling studies
EPISEQ® 16S determines the microbial composition of stools samples based on the 16S rRNA gene. It helps to monitor the microbial flora from dysbiosis towards the recovery of a healthy microbiota in case CDI or to monitor to impact of antibiotics treatment of the stool's microbiota. EPISEQ® 16S helps to characterize a donor’s microbiota in the process of Fecal Microbiota Transplant and assess the presence of C. difficile.
CDIs are an important HAI, and need to be monitored, as part of the Anti-Microbial Stewardship program of your institution.
Discover our booklet on CDIs ”Clostridioides difficile infections, from Diagnosis to Outbreak Management”
References:
- CDC’s 2019 Antibiotic Resistance Threats Report.
- Kelly, C. R., et al. (2021). "ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections." Am J Gastroenterol 116(6): 1124-1147.
- Viprey, V. F., et al. (2022). "A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018." Euro Surveill 27(26).
- McDonald, L. C., et al. (2018). "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)." Clin Infect Dis 66(7): e1-e48.
- Crobach, M. J., et al. (2016). "European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection." Clin Microbiol Infect 22 Suppl 4: S63-81.
- Rand, K. H., et al. (2015). "Multiplex gastrointestinal pathogen panels: implications for infection control." Diagn Microbiol Infect Dis 82(2): 154-157.
